Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 633 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06597942RecruitingPhase 1/Phase 2
Brain stimulation for Alzheimer's disease
This study tests whether a new type of brain stimulation (called repetitive transcranial magnetic stimulation, or rTMS) with a larger coil can improve memory and thinking in people with mild to moderate Alzheimer's disease. It involves multiple sessions of rTMS and MRI scans.
Los Angeles, CaliforniaAges 55–100 - NCT07786116Recruiting
Gut bacteria in Parkinson's disease and related conditions
This study looks at how certain gut bacteria (methanogens) are involved in the progression of Parkinson's disease and related conditions. It aims to understand the connection between gut health and brain health, which may lead to better treatments.
Cambridge, CB2Ages 55 years+ - NCT05655195Recruiting
At-home light and sound therapy for mild Alzheimer’s
This study tests whether regular at-home “gamma” light and sound stimulation can help people with mild Alzheimer’s. Participants start with a month at home and are followed to see how they do during treatment.
Cambridge, MassachusettsAges 65–100 - NCT07234695RecruitingPhase 3
Levetiracetam to prevent seizures in adults with Down syndrome and Alzheimer's
This trial tests if levetiracetam, a seizure medication, can prevent seizures in adults with Down syndrome who also have Alzheimer's disease. It aims to help manage a common complication and improve quality of life.
Granada, AndalusiaAges 40 years+ - NCT06965062Recruiting
Neck surgery for Alzheimer's: a first test
This study tests a new surgery called cervical lymphatic bypass to see if it can help people with Alzheimer's disease. The surgery creates a new connection in the neck to improve drainage of waste from the brain, which may slow memory loss.
SingaporeAges 50–80 - NCT07693140RecruitingPhase 1/Phase 2
Low-dose radiation therapy for Alzheimer's disease
This trial tests if very low doses of radiation to the brain can reduce inflammation and slow memory loss in people with Alzheimer's or similar dementias. It involves monthly clinic visits for a year.
Winter Park, FloridaAges 50 years+ - NCT07842146Recruiting
Urolithin a for people with alzheimer's disease
This study tests a dietary supplement called Urolithin A (Mitopure®) to see if it helps people with mild-to-moderate Alzheimer's disease. You would take the supplement or a placebo, and researchers will track your memory and daily function over time.
PragueAges 55–85 - NCT07803055Recruiting
Blood test for early signs of Alzheimer's disease
This study looks at tiny particles in the blood that may show early signs of Alzheimer's disease. It aims to help with earlier diagnosis and monitoring, which could lead to better care and treatment opportunities.
RomeAges 55–80 - NCT07724132RecruitingPhase 3
Treatments for sustained response in Alzheimer's disease
This study tests whether a treatment (atomoxetine or metformin) can help people with Alzheimer's disease maintain an improved state for at least 18 months. It may help you or a loved one stabilize symptoms and slow disease progression.
CambridgeAges 55 years+ - NCT07604896RecruitingPhase 4
Lecanemab for early Alzheimer's disease with amyloid buildup
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Wenzhou, ZhejiangAges 50–90 - NCT06619613RecruitingPhase 1
Study of CM383 for early Alzheimer's disease
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
HefeiAges 50–85 - NCT07279740RecruitingPhase 2
Brain stimulation plus medication for apathy in dementia
This study tests if combining a type of brain stimulation (repetitive TMS) with a medication (methylphenidate, commonly used for ADHD) can improve apathy in people with dementia. If you have Alzheimer's or mixed dementia and struggle with low motivation, this trial may help you.
Toronto, OntarioAges Any age - NCT07167966Enrolling by invitationPhase 2
Alzheimer's tau vaccine study (AADvac1)
This trial tests a vaccine that targets tau tangles in the brain, which are linked to Alzheimer's. It is part of a larger platform study that combines different experimental treatments.
San Francisco, CaliforniaAges 50–80 - NCT07142278RecruitingPhase 1
Alzheimer's vaccine study for healthy adults ages 40 to 65
This trial tests an experimental vaccine (DUVAX) that targets two proteins linked to Alzheimer's disease: amyloid-beta and tau. It is an early-stage study to check safety and see how the body responds, aiming to prevent or delay the disease.
Miami Lakes, FloridaAges 40–65 - NCT06996730RecruitingPhase 2/Phase 3
Study of donanemab and RG6289 for genetic Alzheimer's disease
This trial tests two medications (donanemab and RG6289) alone or together in people who carry a specific genetic mutation (PSEN1 E280A) that causes early-onset Alzheimer's disease. It aims to see if these drugs can slow or prevent memory loss.
Medellín, AntioquiaAges 25–65 - NCT06957418RecruitingPhase 2
Alzheimer's tau drug study for early stage patients
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
San Francisco, CaliforniaAges 50–80 - NCT06639282RecruitingPhase 2
Testing siponimod for mild Alzheimer's dementia
This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.
Phoenix, ArizonaAges 50–85 - NCT06372821RecruitingPhase 1
Study of NIO752 for Alzheimer's disease
This study tests an experimental drug called NIO752 to see if it can reduce the production of tau protein, which is linked to Alzheimer's disease. Researchers will measure how the drug affects tau in your body using a special technique called SILK.
St Louis, MissouriAges 21–80 - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Phoenix, ArizonaAges 50–92 - NCT05847192Recruiting
Testing brain-signal networks in Alzheimer’s with hallucinations
This study looks at “tau” (a brain protein) and brain-signal patterns in people with Alzheimer’s disease who have psychotic symptoms like hallucinations or delusions. It may help researchers understand what’s happening in the brain and how to better target these symptoms.
Manhasset, New YorkAges 65–85 - NCT02740634Recruiting
Brain imaging study for Alzheimer's disease
This study uses brain scans to understand Alzheimer's disease and related conditions that affect memory, language, or vision. It looks at how changes in the brain happen over time in people with these diagnoses.
Rochester, MinnesotaAges 21–80 - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT06170268Recruiting
Alzheimer's registry for treatment and diagnosis
This registry collects information from people with mild cognitive impairment or dementia due to Alzheimer's disease who are being treated with new FDA-approved therapies. The goal is to track how these treatments work in everyday medical practice.
Chicago, IllinoisAges 18 years+ - NCT07854327Recruiting
Lymphatic drainage treatment for Alzheimer's disease
This trial tests a procedure to improve the brain's waste-clearing system, which may slow the effects of Alzheimer's disease. It's a new approach that aims to help the brain work better.
Siena, TuscanyAges Any age
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 633 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.